Abbott Laboratories

21 hours ago · gurufocus.com

Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Li

4 days ago · prnewswire.com

CROWN-MV trial will evaluate the safety and effectiveness of investigational Cephea mitral valve replacement device Abbott's Cephea is designed to provide a new, minimally invasive option for treating mitral valve disease, the most common type of heart valve ailment 30-day early feasibility study results for Cephea will be presented at TCT 2026 ABBOTT PARK, Ill., Oct. 29, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced today it has initiated the CROWN-MV pivotal trial evaluating the safety and effectiveness of its investigational Cephea™ Mitral Valve System in treating people with symptomatic mitral valve disease who are not candidates for surgery and transcatheter repair.

6 days ago · zacks.com

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

6 days ago · zacks.com

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

6 days ago · seekingalpha.com

FQ4'26 noise from EP/CGM demand headwinds has contributed to Abbott's lowered FY2026 guidance and range-bound stock price action afterwards. Nutrition spin-off may unlock MedTech/Diagnostic/Pharmaceutical's growth, improve margins, and provide investors with new S&P 500-eligible stock. ABT trades at a P/E of 18.79x, below its 5Y mean/MedTech sector, offering a compelling entry point for double-digit upside potential.

6 days ago · fool.com

Abbott Laboratories' third-quarter results were somewhat mixed, with the company's nutrition business still dragging down sales growth. The healthcare leader announced that it would spin off its nutrition segment into a standalone company, which could help boost revenue growth.

7 days ago · prnewswire.com

Powered by whole-genome sequencing and MAESTRO * technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to 5,000 patient-specific variants with a limit of detection below one part per million under high-end inputs 1, 2, 3 The next-generation Oncodetect test builds on more than 20 years of trusted leadership in using genomic information to personalize cancer care  Modeling estimates more than 3 million U.S. patients with solid tumors could potentially benefit from MRD testing † ABBOTT PARK, Ill., Oct. 26, 2026 /PRNewswire/ -- For many people with cancer, completing treatment can bring a new uncertainty: Is my cancer really gone?

7 days ago · seekingalpha.com

Abbott Laboratories remains a Buy, driven by robust device and diagnostics growth and the strategic spin-off of its Nutrition business. Devices and diagnostics now comprise 70% of revenue, with Medical Devices up 7.8% and Diagnostics accelerating post-Exact Sciences acquisition. Spinning off Nutrition is expected to boost ABT's growth rate by 50–100 bps, expand gross margin by 200 bps, and improve operating margin by 100 bps.

10 days ago · prnewswire.com

Beta-CORRECT study shows a 10.6-fold higher risk of recurrence, reinforcing the prognostic value of molecular residual disease (MRD) testing 1 Building on its leadership in colorectal cancer screening with the Cologuard ® test, Abbott is connecting innovations across the cancer care continuum, from early detection to post-treatment monitoring ABBOTT PARK, Ill., Oct. 23, 2026 /PRNewswire/ -- For patients with colorectal cancer, surgery can remove visible cancer, but it can be difficult to know whether minute traces of the disease remain.

11 days ago · zacks.com

Abbott plans to spin off its $8.5B Nutrition business by 2027 while cutting its 2026 sales growth outlook amid diabetes pricing and electrophysiology challenges.